Eurofins will distribute Synthego's sgRNA products to its customers in 44 countries.
The test is based on the company's GARD platform for measuring genetic biomarkers of immune reactions to predict chemical sensitivities.
The system combines sample preparation technology capable of amplifying tens of thousands of locations in the genome with next-generation sequencing.
Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests.
An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.
The deal will close in July and will expand Eurofins' capabilities in areas including DNA sequencing and genetic testing.
The deal is expected to expand Eurofin's clinical diagnostic footprint in Europe.
The lab was opened earlier this year as the company's central genomics lab in North America, offering various genomic services such as DNA sequencing.
The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.